CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $130,561,000 | -29.8% | 1,071,487 | -11.7% | 0.27% | -31.6% |
| Q4 2020 | $185,891,000 | +69.3% | 1,214,102 | -7.5% | 0.39% | +49.0% |
| Q3 2020 | $109,776,000 | +45.4% | 1,312,483 | +27.8% | 0.26% | +34.9% |
| Q2 2020 | $75,499,000 | +73.3% | 1,027,332 | +0.0% | 0.20% | +37.3% |
| Q1 2020 | $43,569,000 | -30.4% | 1,027,325 | +0.0% | 0.14% | -8.4% |
| Q4 2019 | $62,569,000 | +45.9% | 1,027,320 | -1.8% | 0.16% | +39.6% |
| Q3 2019 | $42,889,000 | -9.1% | 1,046,328 | +4.4% | 0.11% | -5.1% |
| Q2 2019 | $47,190,000 | +31.9% | 1,001,918 | 0.0% | 0.12% | +31.5% |
| Q1 2019 | $35,789,000 | +25.3% | 1,001,918 | +0.2% | 0.09% | +9.9% |
| Q4 2018 | $28,570,000 | -35.6% | 1,000,000 | 0.0% | 0.08% | -17.3% |
| Q3 2018 | $44,350,000 | – | 1,000,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |